Abstract
Pancreatic cancer, one of the most challenging malignancies to treat, is characterized by poor survival rates. The identification of novel effective therapies, optimization of treatments for the elderly population, and elucidation of the role of chemoradiotherapy are critical issues. Recent studies presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting have demonstrated advancements in the treatment of this aggressive disease. This review summarizes three notable studies: the phase I trial of IBI389, the phase II GIANT trial, and the phase II/III GABARNANCE trial, each contributing new insights into therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC).
| Original language | English |
|---|---|
| Pages (from-to) | 22-25 |
| Number of pages | 4 |
| Journal | Memo - Magazine of European Medical Oncology |
| Volume | 18 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Feb 2025 |
Keywords
- Borderline resectable
- Claudin 18.2
- Pancreatic cancer
- PDAC
- Targeted therapy
ASJC Scopus subject areas
- Hematology
- Oncology
